Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04094961Phase 1Active Not Recruiting

Ixazomib + Pomalidomide + Dexamethasone In MM

Role: lead

NCT06518551Phase 1Recruiting

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Role: lead

NCT04775550Phase 2Active Not Recruiting

DARA RVD For High Risk SMM

Role: lead

All 3 trials loaded